Friday, October 31, 2014

Trimel in pre-NDA meeting with FDA next month

Trimel in pre-NDA meeting with FDA next month

January 15, 2013 by · 1 Comment 

Tweet Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug application at the end of March. “The pivotal results corroborated what we had anticipated in our statistical modeling and […]

Trimel completes Phase 3 CompleoTRT efficacy trial

Trimel completes Phase 3 CompleoTRT efficacy trial

October 15, 2012 by · Leave a Comment 

Tweet All patients have been dosed in the efficacy portion of Trimel Pharmaceuticals’ (TSX:TRL) CompleoTRT Phase 3 clinical trial for the treatment of male hypogonadism or “Low T”.  Efficacy results are expected to be completed during the current quarter of 2012. Compleo TRT is designed to provide hypogonadal men with the therapeutic effect of restoring […]

Trimel cleared for Tefina study in Canada

Trimel cleared for Tefina study in Canada

June 15, 2012 by · Leave a Comment 

Tweet Health Canada has provided Trimel Pharmaceuticals (TSX:TRL) with a no objection letter, permitting patient enrolment in Canada for the Tefina Phase 2 ambulatory study exploring a use-as-required treatment for women experiencing female orgasmic disorder (FOD), or more commonly referred to as anorgasmia. FOD affects one-in-five women worldwide. Currently, there are no approved FOD treatments, […]

Email Newsletters with Constant Contact
Google+